Brief: Gimv Completes EUR 51 Mln Financing Round In Exciva To Advance Alzheimer's Therapy
20/01/2026 06:41
Jan 20 (Reuters) - Gimv NV GIMV.BR: GIMV LEADS € 51 MILLION SERIES B INVESTMENT ROUND IN EXCIVA TO ADVANCE INNOVATIVE ALZHEIMER’S THERAPY FINANCING ROUND WILL ENABLE EXCIVA TO ADVANCE ITS LEAD COMPOUND, DERAPHAN, INTO A PHASE II CLINICAL TRIAL Source text Further company coverage: GIMV.BR (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))